Clinical trialNASuspended
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)
MRI Imaging to Predict Outcomes of Treatment in PDAC Patients
- Outcome
- Stopped earlyCedars-Sinai Cancer Center Protocol Review and Monitoring Committee has requested several protocol modifications and clarifications regarding study outcomes and completion of data entry for subjects who exited the study. Changes are in the process. (Other)
- Phase
- NA
- Status
- Suspended
- Study type
- Interventional
- Start
- 19 May 2022
- Expected end
- January 2026
- Enrollment
- 36 participants
- Sites
- 1
- Primary outcomes
- Rate of progression-free survival from baseline; Number of participants with R0 resection
- Sponsor
- Other
- Results posted
- No
- Last update
- 17 December 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).
Detailed description public domain (ClinicalTrials.gov)
The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e. vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT).